Identifying the full spectrum of antitumoral effects of FOLR2+ TAMs and determining whether FOLR2+ can mark macrophages with similar or disease-specific programming at the epigenetic, transcriptional and metabolic levels in other cancers and in other pathologies are highly important, and FOLR2 has already been suggested as a target for antibody-based cancer immunotherapy for acute myeloid leukemia [131]. The gene discussed is FOLR2; the disease is acute myeloid leukemia.